Arcturus Therapeutics Holdings Inc. [ARCT] stock Upgrade by Barclays analyst, price target now $25

Arcturus Therapeutics Holdings Inc. [NASDAQ: ARCT] jumped around 3.41 points on Wednesday, while shares priced at $21.69 at the close of the session, up 18.65%. The company report on November 1, 2022 that Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones.

40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines.

Arcturus Therapeutics Holdings Inc. stock is now -41.39% down from its year-to-date (YTD) trading value. ARCT Stock saw the intraday high of $24.65 and lowest of $21.15 per share. The company’s 52-week high price is 48.75, which means current price is +85.38% above from all time high which was touched on 01/04/22.

Compared to the average trading volume of 451.89K shares, ARCT reached a trading volume of 3556865 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Arcturus Therapeutics Holdings Inc. [ARCT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARCT shares is $41.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARCT stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barclays have made an estimate for Arcturus Therapeutics Holdings Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on November 02, 2022. The new note on the price target was released on August 10, 2022, representing the official price target for Arcturus Therapeutics Holdings Inc. stock. Previously, the target price had yet another drop from $86 to $39, while Cantor Fitzgerald kept a Overweight rating on ARCT stock. On May 11, 2022, analysts decreased their price target for ARCT shares from 21 to 18.

The Average True Range (ATR) for Arcturus Therapeutics Holdings Inc. is set at 1.79, with the Price to Sales ratio for ARCT stock in the period of the last 12 months amounting to 13.25. The Price to Book ratio for the last quarter was 3.36, with the Price to Cash per share for the same quarter was set at 11.43.

How has ARCT stock performed recently?

Arcturus Therapeutics Holdings Inc. [ARCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.36. With this latest performance, ARCT shares gained by 29.65% in over the last four-week period, additionally sinking by -3.98% over the last 6 months – not to mention a drop of -53.45% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARCT stock in for the last two-week period is set at 72.05, with the RSI for the last a single of trading hit 79.46, and the three-weeks RSI is set at 66.39 for Arcturus Therapeutics Holdings Inc. [ARCT]. The present Moving Average for the last 50 days of trading for this stock 15.46, while it was recorded at 18.25 for the last single week of trading, and 19.35 for the last 200 days.

Arcturus Therapeutics Holdings Inc. [ARCT]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Arcturus Therapeutics Holdings Inc. [ARCT] shares currently have an operating margin of -1600.06. Arcturus Therapeutics Holdings Inc.’s Net Margin is presently recorded at -1647.98.

Return on Equity for this stock declined to -65.20, with Return on Assets sitting at -46.86.

Arcturus Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 3.10.

Insider trade positions for Arcturus Therapeutics Holdings Inc. [ARCT]

There are presently around $477 million, or 79.30% of ARCT stock, in the hands of institutional investors. The top three institutional holders of ARCT stocks are: FEDERATED HERMES, INC. with ownership of 3,561,097, which is approximately -5.338% of the company’s market cap and around 1.00% of the total institutional ownership; STATE STREET CORP, holding 2,806,918 shares of the stock with an approximate value of $60.88 million in ARCT stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $47.32 million in ARCT stock with ownership of nearly -5.298% of the company’s market capitalization.

Positions in Arcturus Therapeutics Holdings Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 65 institutional holders increased their position in Arcturus Therapeutics Holdings Inc. [NASDAQ:ARCT] by around 2,166,119 shares. Additionally, 51 investors decreased positions by around 1,631,945 shares, while 30 investors held positions by with 18,192,497 shares. The mentioned changes placed institutional holdings at 21,990,561 shares, according to the latest SEC report filing. ARCT stock had 20 new institutional investments in for a total of 575,000 shares, while 16 institutional investors sold positions of 219,983 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here